Skip to main content

Massachusetts

PSYCHEDELIC REGULATIONS FOR BUSINESSES IN MASSACHUSETTS

Massachusetts does not have a regulated commercial market for psychedelics. The state issues no licenses for psychedelic service centers, facilitators, manufacturers, cultivators, or retailers.

Psilocybin, psilocin, DMT, mescaline, ibogaine, and LSD remain controlled substances under state law. Businesses cannot legally produce, sell, distribute, or administer these substances unless they are operating under all required research or medical approvals.

State Controlled-Substance Laws

Massachusetts classifies psychedelic substances under different state drug classes.

  • LSD is listed as a Class B controlled substance.
  • DMT, ibogaine, mescaline, peyote, psilocybin, and psilocin are listed as Class C controlled substances.
  • Unauthorized possession, production, and distribution may result in criminal penalties.

These state classifications are separate from the federal drug schedules. Businesses must comply with both state and federal law.

No Commercial Licensing Framework

Massachusetts has not created a licensing system similar to the regulated psilocybin programs in Oregon and Colorado.

State law does not currently authorize:

  • Retail psychedelic stores
  • Psilocybin service centers
  • Commercial psychedelic cultivation
  • Psychedelic product manufacturing
  • State-licensed facilitators
  • Commercial administration of psilocybin or other prohibited psychedelics

Opening a business, forming a corporation, or receiving a local business permit does not authorize the company to handle controlled substances.

Lawful activity involving these substances is generally limited to research conducted under the required federal, state, and institutional approvals.

Local Decriminalization Measures

Several Massachusetts municipalities have adopted resolutions that make enforcement involving certain entheogenic plants and fungi a low local priority. Somerville, Cambridge, and Northampton were among the first communities to take this approach.

The wording and scope of these measures vary. In general, they direct local officials to deprioritize certain investigations or arrests involving personal possession and use.

Local resolutions do not:

  • Legalize psychedelics under Massachusetts law
  • Protect activity from state or federal enforcement
  • Authorize commercial sales
  • Create business licenses
  • Permit unlicensed treatment or administration

For example, Northampton’s resolution expressly states that it does not authorize the commercial sale of entheogenic plants and fungi.

Businesses should not interpret local deprioritization as permission to sell psychedelics or operate a service center.

Research and Clinical Activity

Massachusetts is home to major medical and academic institutions studying psychedelics. Massachusetts General Hospital launched its Center for the Neuroscience of Psychedelics in 2021.

The center studies how psychedelics affect the brain and explores their possible use in treating mental health conditions. This work takes place in controlled research environments.

Academic research does not create a general commercial market. Researchers and participating institutions must follow applicable rules for clinical trials, controlled substances, patient safety, and institutional review.

The 2024 Psychedelics Ballot Question

Massachusetts voters considered Question 4 during the November 2024 election. The proposal would have allowed limited personal use of certain natural psychedelics and created a regulated system for supervised access.

Voters rejected the measure:

  • 41% voted yes
  • 54% voted no
  • 5% left the question blank

Because Question 4 did not pass, Massachusetts did not establish psychedelic service centers or legalize personal possession under the proposal.

Current Legislative Activity

Lawmakers continue to consider narrower forms of psychedelic reform.

House Bill 4200 proposes a pilot program for psychedelic treatment at no more than three licensed mental health clinics. Participating clinics would provide supervised care and report patient outcomes to the Massachusetts Department of Public Health.

The bill received a favorable committee report in March 2026 and was referred to the Joint Committee on Health Care Financing. It had not become law as of this update.

Senate Bill 1113 proposed reducing penalties for possession of limited amounts of psilocybin and psilocin. In January 2026, the bill was included in a study order rather than enacted.

Earlier proposals, including H.4712 and S.2642 from the previous legislative session, also did not establish a legal commercial market.

Introduced bills do not change the law unless they complete the legislative process and take effect.

Business and Compliance Considerations

Businesses interested in the Massachusetts psychedelic sector should distinguish between lawful research, ancillary activity, and prohibited controlled-substance operations.

Important considerations include:

  • State and federal controlled-substance laws
  • Research and clinical-trial approvals
  • Professional licensing requirements
  • Local ordinances and enforcement policies
  • Advertising and health claims
  • Banking and payment-provider rules

No business should possess, manufacture, sell, or administer controlled psychedelics based solely on a pending bill or local deprioritization measure.

PayRio continues to monitor psychedelic policy as regulated markets develop. Contact PayRio to discuss the compliance needs of a lawful business operating in an emerging industry.

PSYCHEDELIC LEGALIZATION HISTORY IN MASSACHUSETTS

Massachusetts has traditionally prohibited psychedelic substances. Reform efforts began gaining greater attention during the early 2020s.

Municipal Reform and Research

In 2021, municipalities including Somerville, Cambridge, and Northampton adopted local enforcement-priority resolutions involving entheogenic plants and fungi.

That same year, Massachusetts General Hospital launched the Center for the Neuroscience of Psychedelics. The center helped expand scientific research into the possible therapeutic effects of psychedelic substances.

State Legislative Proposals

Massachusetts lawmakers later introduced proposals to study psychedelics, support research, and test supervised treatment models. These measures favored controlled clinical settings rather than retail sales.

None of the earlier proposals created a statewide licensing program.

Question 4

In November 2024, voters rejected Question 4, which proposed limited legalization and regulated access to certain natural psychedelics.

The result left the state’s existing controlled-substance laws in place.

Continuing Reform Efforts

Lawmakers introduced new proposals during the 2025–2026 legislative session. These included a limited-possession bill and a clinical pilot program for licensed mental health facilities.

Neither proposal had established a legal commercial market as of September 2026.

PSYCHEDELIC LEGALIZATION STATUS IN MASSACHUSETTS

Current Status: ILLEGAL outside authorized research and other federally compliant medical settings

Massachusetts law currently:

  • Prohibits unauthorized possession, cultivation, production, sale, and distribution
  • Does not license psychedelic service centers or retail businesses
  • Permits approved research subject to applicable regulatory requirements
  • Allows some municipalities to deprioritize local enforcement without changing state law
  • Does not authorize commercial activity through pending legislation

Massachusetts remains active in psychedelic research and policy discussions. Any future business opportunities will depend on new legislation, regulations, licensing rules, and federal requirements.

LAST UPDATED 9/2/2026 – Laws can be revised and updated frequently, so please keep this in mind.